Oral corticosteroids in asthma: A review of benefits and risks

Canadian Respiratory Journal

Volumn 14, Issue SUPPL. C, 2007, Pages

  Schellenberg, Robert ^a   Adachi, Jonathan D R ^b   Bowie, Dennis ^c   Brown, Jacques ^d   Guenther, Lyn ^e   Kader, Tina ^f   Trope, Graham E ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Asthma; Oral corticosteroids

Indexed keywords

ALENDRONIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; ETIDRONIC ACID; FLUTICASONE PROPIONATE PLUS SALMETEROL; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; OMALIZUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; THEOPHYLLINE;

ACNE; ADRENAL CORTEX ATROPHY; ALLERGIC RHINITIS; ALPHA ANTITRYPSIN DEFICIENCY; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BEHAVIOR; BONE NECROSIS; BRAIN ATROPHY; BRONCHIECTASIS; BRONCHIOLITIS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COGNITION; CONGESTIVE HEART FAILURE; CUSHING SYNDROME; CYSTIC FIBROSIS; DELAYED PUBERTY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG CLASSIFICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSLIPIDEMIA; ERYTHEMA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOGONADISM; IMMUNE DEFICIENCY; INTRAUTERINE GROWTH RETARDATION; LUNG EMBOLISM; LUNG FUNCTION; LUNG TUMOR; MACULOPAPULAR RASH; MEMORY; METABOLIC DISORDER; MUSCLE ATROPHY; OSTEOPOROSIS; PANCREATITIS; PATHOLOGIC FRACTURE; PEPTIC ULCER; PERIORAL DERMATITIS; PETECHIA; POTASSIUM EXCRETION; PRIORITY JOURNAL; PURPURA; REFLUX ESOPHAGITIS; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SODIUM RETENTION; STRIA; TELANGIECTASIA; THROMBOSIS; TRACHEOBRONCHOMEGALY; URTICARIA; VOCAL CORD DISORDER; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

EID: 39049160766     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/160691     Document Type: Review

References (54)

1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med. 2005;353:1711-23.
2. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152(6 pt 2):S125-40.
3. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:451-68.
4. Alvarez J, Surs W, Leung DY, et al. Steroid-resistant asthma: Immunologic and pharmacologic features. J Allergy Clin Immunol 1992;89:714-21.
5. Spahn JD, Leung DY, Szefler SJ. New insights into the pathogenesis and management of steroid-resistant asthma. J Asthma 1997;34:177-94.
6. Woolcock AJ. Steroid resistant asthma: What is the clinical definition? Eur Respir J 1993;6:743-7.
7. Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001;CD002178.
8. Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2001;CD000195.
9. Fiel SB, Swartz MA, Glanz K, et al. Efficacy of short-term corticosteroid therapy in outpatient treatment of acute bronchial asthma. Am J Med 1983;75:259-62.
10. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44.
11. Boulet LP, Becker A, Berube D, et al. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161(11 Suppl):S1-61.
12. Becker A, Lemière C, Bérubé D, et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ 2005;173(6 Suppl):S3-11.
13. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. (Version current at September 28, 2007).
14. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. NIH publication no. 97-4051, July 1997.
15. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. NIH publication no. 03-5074, June 2003.
16. Beam WR, Weiner DE, Martin RJ. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am Rev Respir Dis 1992;146:1524-30.
17. Fiel SB, Vincken W. Systemic corticosteroid therapy for acute asthma exacerbations. J Asthma 2006;43:321-31.
18. Cohen D, Adachi JD. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochemn Mol Biol 2004;88:337-49.
19. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 2002;13:777-87.
20. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 2005;56:178-8.
21. Melton LJ 3rd, Patel A, Achenbach SJ, et al. Long-term fracture risk among children with asthma: A population-based study. J Bone Miner Res 2005;20:564-70.
22. McKee MD, Waddell JP, Kudo PA, et al. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: A report of 15 cases. CMAJ 2001;164:205-6.
23. Fardet L, Cabane J, Lebbé C, et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: A prospective study. J Am Acad Dermatol 2007;57:604-9.
24. Schoepe S, Schäcke H, May E, Asdullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006;15:406-20.
25. Autio P, Oikarinen A, Melkko J, et al. Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol 1994;131:660-3.
26. Kimura T, Doi K. Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids. Toxicol Pathol 1999;27:528-35.
27. Kang S, Kim KJ, Griffith CE, et al. Topical tretinoin (retinoic acid) improves early stretch marks. Arch Dermatol 1996;132:519-26.
28. McDaniel DH, Ash K, Zukowski M. Treatment of stretch marks with the 585-nm flashlamp-pumped pulsed dye laser. Dermatol Surg 1996;22:332-7.
29. Suh D-H, Chang K-Y, Son H-C, et al. Radiofrequency and 585-nm pulsed dye laser treatment of striae distensae: A report of 37 Asian patients. Dermatol Surg 2007;33:29-34.
30. Oishi Y, Fu ZW, Ohnuki Y, et al. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: Effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002;147:859-68.
31. Brauchle M, Fässler R, Werner S. Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing. J Invest Dermatol 1995;105:579-84.
32. Räsänen L, Hasan T. Allergy to systemic and intralesional corticosteroids. Br J Dermatol 1993;128:407-11.
33. Graham C, Vadas P. Systemic allergic reactions to corticosteroids. Practical Allergy & Immunology 1995;10:182-5.
34. Lauerma AI, Reitamo S. Contact allergy to corticosteroids. J Am Acad Dermatol 1993;28:618-22.
35. Yawalker N, Hari Y, Helbling A, et al. Elevated serum levels of interleukins 5, 6, and 10 in a patient with drug-induced exanthem caused by systemic corticosteroids. J Am Acad Dermatol 1998;39:790-3.
36. Wilkinson SM, Cartwright PH, English JS. Hydrocortisone: An important cutaneous allergen. Lancet 1991;337:761-2.
37. Ventura MT, Calogiuri GF, MAtino MG, et al. Alternative glucocorticoids for use in cases of adverse reaction to systemic glucocorticoids: A study on 10 patients. Br J Dermatol 2003;148:139-41.
38. Goossens A, Matura M, Degreef H. Reactions to corticosteroids: Some new aspects regarding cross-sensitivity. Cutis 2000;65:43-5.
39. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
40. Varas-Lorenzo C, Rodriguez LA, Maguire A, et al. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis 2007;192:376-83.
41. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006;166:1016-20.
42. Bello CE, Garrett SD. Therapeutic issues in oral glucocorticoid use. Lippincotts Prim Care Pract 1999;3:333-41.
43. British Thoracic and Tuberculosis Association. Inhaled corticosteroids compared with oral prednisone in patients starting long-term corticosteroid therapy for asthma. Lancet 1975;2:469-73.
44. Shibli-Rahhal A, Van Beek M, Schlechte JA. Cushing's syndrome. Clin Dermatol 2006;24:260-5.
45. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
46. Black RL, Oglesby RB, von Sallmann L, et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960;174:166-71.
47. Carnahan MC, Goldstein DA. Ocular complications of topical, periocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-83.
48. Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 2002;85:61-75.
49. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: A review of the literature. Eye 2006;20:407-16.
50. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483-92.
51. Corrigan CJ. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med 2002;1:47-54.
52. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-8.
53. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006;174:753-62.
54. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-37.